Pharsight

1. Forfivo Xl patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US7674479	December, 2008	Decision	Horst G. Zerbe et al

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7674479	TWI PHARMS	Sustained-release bupropion and bupropion/mecamylamine tablets	Jun, 2027 (3 years from now)

Market Authorisation Date: 10 November, 2011

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
450 mg	28 Feb, 2013	1		25 Jun, 2027	Extinguished

Strength	Dosage	Availability
450MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5763493	GLAXOSMITHKLINE	Stabilized pharmaceutical	Aug, 2013 (10 years ago)
US5427798	GLAXOSMITHKLINE	Controlled sustained release tablets containing bupropion	Aug, 2013 (10 years ago)
US5731000	GLAXOSMITHKLINE	Stabilized pharmaceutical composition containing bupropion	Aug, 2013 (10 years ago)
US5358970	GLAXOSMITHKLINE	Pharmaceutical composition containing bupropion hydrochloride and a stabilizer	Aug, 2013 (10 years ago)

Market Authorisation Date: 04 October, 1996

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
200MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
150MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
100MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
50MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6096341	BAUSCH	Delayed release tablet of bupropion hydrochloride	Oct, 2018 (5 years ago)

Market Authorisation Date: 28 August, 2003

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
150 mg and 300 mg	21 Sep, 2004	1	14 Dec, 2006	30 Oct, 2018	Eligible

Strength	Dosage	Availability
300MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
150MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5731000	GLAXOSMITHKLINE	Stabilized pharmaceutical composition containing bupropion	Aug, 2013 (10 years ago)
US5427798	GLAXOSMITHKLINE	Controlled sustained release tablets containing bupropion	Aug, 2013 (10 years ago)
US5763493	GLAXOSMITHKLINE	Stabilized pharmaceutical	Aug, 2013 (10 years ago)
US5358970	GLAXOSMITHKLINE	Pharmaceutical composition containing bupropion hydrochloride and a stabilizer	Aug, 2013 (10 years ago)

Market Authorisation Date: 14 May, 1997

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL